CC-122, a novel cereblon-modulating agent, in combination with obinutuzumab (GA101) in patients with relapsed and refractory (R/R) B-cell non-hodgkin lymphoma (NHL)

J. M. Michot, R. Bouabdallah, J. K. Doorduijn, U. Vitolo, M. J. Kersten, A. Chiappella, P. L. Zinzani, M. Pourdehnad, Z. Nikolova, V. Ribrag

Research output: Contribution to JournalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)iii9
JournalAnnals of oncology
Publication statusPublished - 2018

Cite this